Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;18(28):3199-3215.
doi: 10.2217/fon-2022-0407. Epub 2022 Sep 7.

Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon

Jenny Furlanetto  1 , Frederik Marmé  2 , Sibylle Loibl  1   3
Affiliations
Review

Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon

Jenny Furlanetto et al. Future Oncol. 2022 Sep.

Abstract

Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor cells (bystander effect). SG showed efficacy and safety in several epithelial tumors. The phase III ASCENT trial led to the approval of SG (10 mg/kg, d1,8 q3w) in patients with advanced or metastatic triple-negative breast cancer (TNBC) who have received ≥2 prior systemic therapies, including ≥1 for metastatic disease. The phase III TROPiCS-02 trial in heavily pretreated advanced hormone receptor (HR)-positive breast cancer has recently shown an improvement in progression-free survival for patients treated with SG compared to single-agent chemotherapy. The phase III post-neoadjuvant SASCIA study in early high-risk TNBC and HR-positive breast cancer is currently recruiting patients.

Keywords: antibody–drug conjugate; early breast cancer; metastatic breast cancer; sacituzumab govitecan.

Plain language summary

Sacituzumab govitecan is a new treatment for metastatic triple-negative breast cancer. Triple-negative means that the three most commonly identified proteins are not found on the surface of cancer cells (estrogen or progesterone receptor and high level of the protein HER2). Metastatic breast cancer indicates that the breast cancer has spread to other parts of the body. Sacituzumab govitecan is a monoclonal antibody, a therapeutic antibody or protein that can attach a specific target on the surface of cancer cells known as Trop-2. The antibody carries a medication known as SN-38, which is released within and around the cancer cells, causing the destruction of cancer cells. The ASCENT trial compared 3 acituzumab govitecan with chemotherapy, which is a treatment that kills cancer cells or stops them from dividing. The trial showed that patients with advanced triple-negative breast cancer who took sacituzumab govitecan lived longer than those who took a different chemotherapy regimen while on the study. The TROPiCS-02 trial showed that also patients with a metastatic cancer expressing estrogen or progesterone receptor, known as hormone-receptor positive breast cancer, derived benefit from sacituzumab govitecan. The SASCIA trial will define if patients with early breast cancer receiving sacituzumab govitecan after surgery might live longer without the recurrence of cancer. Early-stage breast cancer means that the cancer has not spread to other parts of the body and can be completely removed with surgery.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

LinkOut - more resources